Feasibility Study CORPPS
- Conditions
- Laryngeal NeoplasmsEsophageal Neoplasm
- Registration Number
- NCT05406024
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
The incidence of cancer in France has increased by +135% to reach nearly 400,000 new cases in 2018. The ten-year cancer control strategy 2021-2030 and the health innovation plan have defined strategic axes. Almost all of these axes are addressed in our project. Firstly, the main objective of our study is to improve the quality of life of patients. Secondly, pharyngolaryngeal and oesophageal cancers are among the cancers with a poor prognosis in adults. Thirdly, the project provides access to personalised supportive care for all patients at all times. Finally, the secondary objectives of this study are the prevention of post-operative complications (infectious, thrombo-embolic, pain...).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- Hospitalized for initial surgical management of esophageal or laryngeal cancer
- Admitted to a conventional ward after partial oesophagectomy or total laryngectomy in a neoplastic setting
- Patient giving consent to participate in the study
- Affiliated to the compulsory health insurance scheme, regardless of the scheme
- Patient who did not follow the previously described course of care prior to admission to the ward
- Esophagectomy with total circular pharyngo-laryngectomy
- Total esogastrectomy
- Illiterate, visually impaired patient
- Minor, or adult under guardianship or curatorship, under judicial protection, person deprived of liberty
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acceptability rate At 1 year Realization of the ratio between the number of inclusion proposals and the number of accepted inclusions.
- Secondary Outcome Measures
Name Time Method Adherence to exercise intervention program: Number of exercises completed Discharge from hospital if it occurs before 30 days or at Day 30 Satisfaction by the System Usability Scale Discharge from hospital if it occurs before 30 days or at Day 30 Adherence to exercise intervention program: type of exercises completed Discharge from hospital if it occurs before 30 days or at Day 30 Adherence to exercise intervention program: Number of login Discharge from hospital if it occurs before 30 days or at Day 30 Warwick-Edinburgh Mental Wellbeing Scales Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 The well-being and theu quality of life will be assessed using the Warwick-Edinburgh Mental Wellbeing Scales Each item is scored on a range from 1 to 5. The total score will be between 14 and 70, with lower scores indicating poor wellbeing, and higher scores indicating greater wellbeing. Very low wellbeing is defined as a score of ≤ 45. A substantial decrease in wellbeing is a decrease by 5 or more points.
Adherence to exercise intervention program: retention rate Discharge from hospital if it occurs before 30 days or at Day 30 Classification de Clavien-Dindo At day 30 Evaluation of the incidence of postoperative complications based on the Clavien-Dindo classification grade II
Visual Analogue Scale Before and after each activity Measure the pain in the scale from 0 to 10
Instant Well-Being Evaluation (IWBE) Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 It consists of a graduated scale: the patient must position a cursor, the position on the left corresponding to "I feel very well" and the position on the right to "I do not feel well". The patient is guided by a pictogram (happy, neutral or sad face)
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30) Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 The quality of life will be assessed using the EORTC-QLQ-C30 The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many clinical trials in oncology
EuroQuol 5 Dimensions (EQ-5D-5L) Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 The quality of life will be assessed using the EuroQuol 5 Dimensions The EQ-5D-5L questionnaire will be used to estimate the impact on subjects' health-related quality of life and provides a description of subjects' problems by dimensions (descriptive system), a score for overall self-rated health (visual analogue scale \[VAS\]) as well as an index score (EQ-5D-5L index). EQ-5D index score range: 0 to 1 and EQ-5D-VAS: range 0 to 100. A higher score indicates better self reported health status.